Emily Dworkin

Leukemia and AYA pharmacist @UChicagoMed @UCM_aya. PharmD @uiowa | PGY1/PGY2 @UWHealth. views = my own.

[Anand Patel @Anand_88_Patel]

Full abstracts from #ASCO24 are out!

Check out our abstract led by @LeahGoldberg20 on peg-asparaginase dosing in ALL and therapeutic levels achieved with lower doses #leusm

https://t.co/NAPF9E0F1A

[Emily Dworkin @emdworkin]

@Anand_88_Patel @UChicagoLeuk @UChicagoHemOnc @UCCancerCenter Congratulations!!!

[Emily Dworkin @emdworkin]

So proud of my good friend @ErinMcCreary! She is a rockstar pharmacist, tremendous leader and my favorite resource for all my ID questions.

[Erin McCreary @ErinMcCreary]

thank you, @SIDPharm, for the greatest honor. I can't wait to serve with this amazing Board!

[Emily Dworkin @emdworkin]

@Anand_88_Patel Congratulations!!!

[UChicago Medicine @UChicagoMed]

.@UCCancerCenter is joining an elite national network to lead the charge in evidence-based cancer treatments and improved patient outcomes. https://t.co/Y5tl3aVGXW

[Ilayna Mehrtens, PhD @IlaynaM]

Anyone know anyone with @falloutboy who could help a badass chicago-based AYA cancer survivor's dreams come true this June?? 🤩🤠

[Erin McCreary @ErinMcCreary]

aspiring pharmacists— I will read and provide feedback on your cover letters and CVs for free. the journey is hard and expensive enough as is, please don’t buy in to things like this. especially when they’re dragging you.

[Greg Roloff @RoloffGreg]

We meet the occasional AML pt with a FLT3 mutation outside the classic ITD/TKD sites. A common one is FLT3 N676K. Check out our new @UChicagoLeuk analysis of this atypical variant's responsiveness to FLT3i @michaelwd @UCCancerCenter @UCHemOncFellows
https://t.co/1V2zGyqqSd

[Emily Dworkin @emdworkin]

@JessieSig There is no data saying asparlas improves OS, has less toxicity or improves QOL over oncaspar so when did it become okay for a pharma company to control how we treat patients? It just feels so cringey

[Anand Patel @Anand_88_Patel]

Our review on newly-dx AML is in @JCOOP_ASCO! Had the pleasure of writing it w/ star fellow (@UCHemOncFellows) Dr Jen Cooperrider, star resident (@MedChiefs) Dr Navika Shukla & my wonderful colleague @mariamtn89! #leusm

https://t.co/6hAc1Y6qdh

[Joshua Zeidner MD @LeukDocJZ]

Excited to present our newest paper in @JAMAOnc highlighting the discrepancy of QTc values and its effect in mgmt of onc pts. This was a true tour de force led by @danielrich21, @pcparish, @Benyam_Muluneh @UNC_Lineberger /1
https://t.co/h6J875eEqS

[Emily Dworkin @emdworkin]

@RoloffGreg My favorite team! Congrats on 1 year of fellowship completed!

[Erin McCreary @ErinMcCreary]

nobody:

absolutely fucking nobody:

🇺🇸: let’s force women to give birth despite our abysmal maternal mortality rate (for which we have done no major health reform) and then do nothing to keep the kids alive either (because 2A ✌🏻)

[Emily Dworkin @emdworkin]

@ErinMcCreary @krutu8 @Dyson @emilylheil @kaitmccreary @etshannon @marianapelts @julietmccreary Haven’t had a bad hair day since April 22, 2021. The day my @Dyson arrived.

[Emily Dworkin @emdworkin]

@ErinMcCreary @krutu8 @Dyson @emilylheil @kaitmccreary @etshannon @marianapelts @julietmccreary I’m blown away by how quickly it dries my hair

[University of Chicago Hem/Onc Fellows @UCHemOncFellows]

Congratulations to Dr. @AyaOncologist, our fellow Dr. Sheade, and Dr. Stock on their new manuscript in @JCOOP_ASCO. #AYA #leusm

https://t.co/0hILKXTz4n

[Emily Dworkin @emdworkin]

So proud of our PGY2 residents in Oncology @UChicagoMedRx. They have worked so hard and are going to do some awesome things in their careers! #HOPAAC22

[UChicago Medicine Pharmacy Residency Programs @UChicagoMedRx]

Congrats to our PGY2 Oncology Pharmacy Residents for their research poster presentations at @HOPArx! Pictured here is Zaheera Shabbir @Zee_PharmD. Her research evaluated tacrolimus levels and GVHD in allogeneic HSCT recipients.

Congrats!

#HOPA #oncology #PharmRes #TwitteRx

[Emily Dworkin @emdworkin]

What an amazing #HOPAAC22. Had a great time seeing old friends and meeting new ones, learning a TON, and debating @JessieSig about the optimal induction therapy for AML.